Download PDF
CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR
DOI: 10.1055/s-0044-1786711
Original Article

Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Amelia Wong 
1   Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, United States
,
Shirley Cheng 
2   John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States
,
Anthony Herrera
3   Department of Radiology, The Queen's Medical Center, Honolulu, Hawaii, United States
,
Linda Wong 
1   Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to identify factors that increase risk of liver decompensation resulting in hospital admissions after TARE.

Methods Patients who received Y90 as their first treatment during 2012 to 2022 were identified from a prospectively collected database of 1675 HCC patients. Clinically significant hepatic decompensation was defined as total bilirubin more than or equal to 3 mg/dL or any increase in Model for End-stage Liver Disease (MELD) score resulting in readmission within 60 days or death.

Results Of 137 patients, 7 (5.1%) developed hepatic decompensation requiring admission within 30 days and an additional 8 (10.9%) within 60 days. Two of these patients (1.4%) died and two (1.4%) required urgent transplant within 2 months. Preprocedure albumin less than 3.5 gm/dL (p = 0.0207), international normalized ratio more than 1.2 (p = 0.017), ascites (p = 0.036), elevated MELD (p = 0.012), and Child-Pugh (p = 0.007) scores were significant predictors of decompensation, while creatinine and sodium were not. Patients with Child-Pugh B score were three to four times more likely to decompensate (28 vs. 8%) compared to Child-Pugh A. For every unit increase in Child-Pugh score more than 6, odds of decompensation increased by a factor of 2.15.

Conclusion Y90 TARE is safe and effective; however, 10.9% patients require readmission for worsened liver function. Because ascites is a significant factor in predicting decompensation and all patients require adequate renal function to receive Y90 TARE, Child-Pugh score may be more useful than MELD for patient selection. Further risk stratification may be required for those with a Child-Pugh score more than or equal to 7.

Keywords

hepatocellular carcinoma - yttrium 90 - transarterial radioembolization

Ethical approval

This study was approved by the Institutional Review Board of The Queen's Medical Center and complies with ethical regulations.




Publication History

Article published online:
13 May 2024

© 2024. Indian Society of Vascular and Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedGoogle Scholar
  • 3 Sun J, Guo R, Bi X. et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition). Liver Cancer 2022; 11 (04) 315-328
    CrossrefPubMedGoogle Scholar
  • 4 Chung SW, Park MK, Cho YY. et al. Effectiveness of transarterial chemoembolization-first treatment for advanced hepatocellular carcinoma: a propensity score matching analysis. J Hepatocell Carcinoma 2021; 8: 587-598
    CrossrefPubMedGoogle Scholar
  • 5 Silva JP, Berger NG, Tsai S. et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford) 2017; 19 (08) 659-666
    CrossrefPubMedGoogle Scholar
  • 6 Bhangoo MS, Karnani DR, Hein PN. et al. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015; 6 (05) 469-478
    PubMedGoogle Scholar
  • 7 Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol 2014; 5 (03) 178-189
    PubMedGoogle Scholar
  • 8 Woerner AJ, Johnson GE. Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma. Hepatoma Res 2022; DOI: 10.20517/2394-5079.2021.122.
    CrossrefPubMedGoogle Scholar
  • 9 Kim SP, Cohalan C, Kopek N, Enger SA. A guide to 90Y radioembolization and its dosimetry. Phys Med 2019; 68: 132-145
    CrossrefPubMedGoogle Scholar
  • 10 Kennedy AS, McNeillie P, Dezarn WA. et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74 (05) 1494-1500
    CrossrefPubMedGoogle Scholar
  • 11 Garin E, Tselikas L, Guiu B. et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 Trial. J Nucl Med 2024; 65 (02) 264-269
    CrossrefPubMedGoogle Scholar
  • 12 Knight GM, Gordon AC, Gates V. et al. Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2023; 34 (07) 1214-1225
    CrossrefPubMedGoogle Scholar
  • 13 Kennedy A, Nag S, Salem R. et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (01) 13-23
    CrossrefPubMedGoogle Scholar
  • 14 Ad M, Kim N, Kim A, Ad M. 03:27 PM Abstract No. 328 Hospital readmission rate after yttrium-90 radioembolization (Y90 RE): a 233-patient cohort evaluation. J Vasc Interv Radiol 2019; 30 (03) S145
    CrossrefPubMedGoogle Scholar
  • 15 Aberle S, Kenkel D, Becker AS. et al. Outpatient yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiol Med (Torino) 2020; 125 (10) 971-980
    CrossrefPubMedGoogle Scholar
  • 16 Riaz A, Lewandowski RJ, Kulik LM. et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20 (09) 1121-1130 , quiz 1131
    CrossrefPubMedGoogle Scholar
  • 17 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol 2014; 4: 198
    CrossrefPubMedGoogle Scholar
  • 18 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021; 74 (05) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 19 Benson AB, D'Angelica MI, Abbott DE. et al; NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancers, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19 (05) 541-565
    CrossrefPubMedGoogle Scholar
  • 20 Guidelines Version NCCN. 2.2023 Hepatocellular Carcinoma [Internet]. 2023 [cited 9/18/2023]. Accessed April 19, 2024 at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514
    PubMed
  • 21 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 22 Goin JE, Salem R, Carr BI. et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16 (2 Pt 1): 205-213
    CrossrefPubMedGoogle Scholar
  • 23 United States Census Bureau. Accessed April 19, 2024 at: https://www.census.gov/quickfacts/fact/table/US/PST045222
    PubMed
  • 24 Sangro B, Gil-Alzugaray B, Rodriguez J. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
    CrossrefPubMedGoogle Scholar
  • 25 Szyszko T, Al-Nahhas A, Tait P. et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun 2007; 28 (01) 21-24
    CrossrefPubMedGoogle Scholar
  • 26 Young JY, Rhee TK, Atassi B. et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18 (11) 1375-1382
    CrossrefPubMedGoogle Scholar
  • 27 Lee HM, Alder L, Nguyen M. et al. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma. J Gastrointest Oncol 2023; 14 (03) 1378-1391
    CrossrefPubMedGoogle Scholar
  • 28 Brown DB, Fundakowski CE, Lisker-Melman M. et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15 (11) 1209-1218
    CrossrefPubMedGoogle Scholar